"You have to look at the cell-free DNA results with a grain of salt and with some degree of sophistication in terms of what you can act on as a predictive biomarker in the blood." Within any robust multidisciplinary treatment team, pathologists are a very valuable part of the decision-making process. They are often the first to determine a cancer diagnosis when samples are seen in the lab, and they can offer deeper insights into the genomics of specific tumors, which serve to guide treatment selection across settings. In an interview with ONCOLOGY?, Lynette M. Sholl, MD, spoke about her career as a pathologist as well as the ever-evolving role of circulating tumor DNA (ctDNA) in the field of oncology. Sholl details how her early career and what she has learned have helped shed light on best practices between pathologists and oncologists.
展开▼
